https://www.aigom.it/wp-content/uploads/2024/06/ART.25.6.png1205950Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-24 07:06:202024-06-24 07:06:20OSIMERTINIB AFTER CHEMORADIOTHERAPY IN STAGE III EGFR-MUTATED NSCLC.
https://www.aigom.it/wp-content/uploads/2024/06/ART18.6.png1080935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-18 09:01:252024-06-18 09:01:25IMPROVED CLINICAL STAGING SYSTEM FOR LOCALIZED PANCREATIC CANCER USING THE ABC FACTORS: A TAPS CONSORTIUM STUDY
https://www.aigom.it/wp-content/uploads/2024/06/CHICAGO.png684845Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-06-18 07:50:522024-06-18 07:53:57LE NOVITA’ DA CHICAGO 2024 | 17 giugno 2024 ore 15.00-18.00
https://www.aigom.it/wp-content/uploads/2024/06/h2024loc.png577400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-11 07:47:292024-06-11 07:47:29OECI ONCOLOGY-ONCOLOGY DAYS OECI 46 HELSINKI 12-14 GIUGNO 2024
https://www.aigom.it/wp-content/uploads/2024/06/ART11.06.png1257935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-10 08:38:262024-06-10 08:38:26TRASTUZUMAB PLUS GEMCITABINE-CISPLATIN FOR TREATMENT-NAïVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BILIARY TRACT ADENOCARCINOMA: A MULTICENTER, OPEN-LABEL, PHASE II STUDY (TAB)
https://www.aigom.it/wp-content/uploads/2024/06/ART.04.06.png1137935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-03 08:24:502024-06-03 08:24:50PERIOPERATIVE DURVALUMAB FOR RESECTABLE NON-SMALL-CELL LUNG CANCER
